Morgan Stanley Downgrades ResMed (RMD) to Underweight

July 14, 2008 7:47 AM EDT

Morgan Stanley downgrades ResMed (NYSE: RMD) from Equalweight to Underweight.

ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of -disordered breathing, including obstructive sleep apnea, and other respiratory disorders that occur during sleep.


Related Categories

Downgrades

Stocks Mentioned

RMD 44.82

-0.71 -1.56%
Volume: 631,820
Track RMD


Related Entities


Add Your Comment